SAN || Conference News

Real-world use supports belimumab clinical trial data

Posted on: 08/07/2014 - 16:20

PARIS – Belimumab produced significant clinical improvement in 74% of patients with systemic lupus erythematosus who took it over a 6-month period, reducing disease symptoms and steroid use and...

Field of Interest: Rheumatology
Type: News Item

SLE patients in remission safely stop immunotherapy

Posted on: 30/06/2014 - 18:45

PARIS – When patients with lupus who were in remission on an immunosuppressant drug and a low dosage of prednisone stopped their immunosuppressant, 70% remained flare free 2 years off...

Field of Interest: Rheumatology
Type: News Item

FVC inadequate when assessing scleroderma lung disease

Posted on: 18/06/2014 - 22:40

PARIS – The traditional way to assess the status of interstitial lung disease in patients with systemic sclerosis, forced vital capacity, may not be the best way, based on a new analysis of 83...

Field of Interest: Rheumatology
Type: News Item

FVC inadequate when assessing scleroderma lung disease

Posted on: 18/06/2014 - 22:40

PARIS – The traditional way to assess the status of interstitial lung disease in patients with systemic sclerosis, forced vital capacity, may not be the best way, based on a new analysis of 83...

Field of Interest: Dermatology
Type: News Item

Copaxone lipoatrophy far more common than reported

Posted on: 09/06/2014 - 17:30

DALLAS – The risk of lipoatrophy with glatiramer acetate is greater than 60%, according to a review of 73 multiple sclerosis patients at one clinic. The risk is "substantially higher than...

Field of Interest: Dermatology
Type: News Item

Atopic dermatitis update taps top therapy choices

Posted on: 06/06/2014 - 22:05

WAIKOLOA, HAWAII – The 2014 update of the American Academy of Dermatology guidelines on atopic dermatitis take a strong stance in favor of the use of topical calcineurin inhibitors as topical...

Field of Interest: Dermatology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More